

Claims

1. A binding molecule that is adapted to specifically bind to tau, comprising:
a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1,
a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2,
a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3,
a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4,
a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and
a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6,
wherein the binding molecule is capable of inhibiting aggregation of tau.
2. A binding molecule according to claim 1, wherein the binding molecule comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.
3. A binding molecule according to claim 1, wherein the binding molecule is a human monoclonal antibody, or an antigen-binding fragment thereof.
4. A binding molecule according to claim 2, wherein the binding molecule is a human monoclonal antibody, or an antigen-binding fragment thereof.
5. A method of inhibiting aggregation of tau protein, comprising exposing the tau protein to a binding molecule according to claim 1.
6. A method of inhibiting aggregation of tau protein, comprising exposing the tau protein to a binding molecule according to claim 2.
7. A binding molecule according to claim 1, for use in the diagnosis prophylaxis or treatment of a neurodegenerative disease that involves accumulation of tau, and/or pathological aggregation of tau.

8. A binding molecule according to claim 2, for use in the diagnosis, prophylaxis or treatment of a neurodegenerative disease that involves accumulation of tau, and/or pathological aggregation of tau.
9. A binding molecule for use according to claim 7, wherein the neurodegenerative disease is Alzheimer's disease.
10. A binding molecule according to claim 8, wherein the neurodegenerative disease is Alzheimer's disease.
11. A nucleic acid molecule encoding a binding molecule according to claim 1.
12. A nucleic acid molecule encoding a binding molecule according to claim 2.
13. A vector, comprising a nucleic acid molecule according to claim 11.
14. A vector, comprising a nucleic acid molecule according to claim 12.
15. A pharmaceutical composition, comprising:
a binding molecule according to claim 1, and
a pharmaceutically acceptable carrier or excipient.
16. A pharmaceutical composition, comprising:
a binding molecule according to claim 2, and
a pharmaceutically acceptable carrier or excipient.
17. An immunoconjugate, comprising:
at least one binding molecule according to claim 1, and
at least one tag.
18. An immunoconjugate, comprising:

at least one binding molecule according to claim 2, and
at least one tag.

19. A pharmaceutical composition comprising:
an immunoconjugate according to claim 17, and
a pharmaceutically acceptable carrier or excipient.
20. A pharmaceutical composition, comprising:
an immunoconjugate according to claim 18, and
a pharmaceutically acceptable carrier or excipient.